UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

The lancet respiratory medicine, 2015-04, Vol.3 (4), p.301-309

2015

Volltextzugriff (PDF)

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

The lancet oncology, 2013-10, Vol.14 (11), p.1104-1111

2013

Volltextzugriff (PDF)

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Journal of clinical oncology, 2012-07, Vol.30 (20), p.2522-2529

2012

Volltextzugriff (PDF)

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

The lancet oncology, 2012-09, Vol.13 (9), p.879-886

2012

Volltextzugriff (PDF)

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

Journal of translational medicine, 2004-06, Vol.2 (1), p.18-18, Article 18

2004

Volltextzugriff (PDF)

Biology and Clinical Applications of CD40 in Cancer Treatment

Seminars in oncology, 2010-10, Vol.37 (5), p.517-523

2010

Volltextzugriff (PDF)

Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness

Journal of translational medicine, 2024-01, Vol.22 (1), p.35-24, Article 35

2024

Volltextzugriff (PDF)

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine

Cancer research (Chicago, Ill.), 2004-12, Vol.64 (24), p.9167-9171

2004

Volltextzugriff (PDF)

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

Journal of cellular physiology, 2007-08, Vol.212 (2), p.330-344

2007

Volltextzugriff (PDF)

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

Annals of the New York Academy of Sciences, 2012-10, Vol.1270 (1), p.8-12

2012

Volltextzugriff (PDF)

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Clinical cancer research, 2007-06, Vol.13 (11), p.3333-3338

2007

Volltextzugriff (PDF)

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Oncoimmunology, 2016-02, Vol.5 (2), p.e1071007-e1071007

2016

Volltextzugriff (PDF)

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Oncogene, 2003-09, Vol.22 (42), p.6564-6569

2003

Volltextzugriff (PDF)

Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model

Clinical cancer research, 2000-05, Vol.6 (5), p.2037-2043

2000

Volltextzugriff (PDF)

The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

Clinical cancer research, 2006-06, Vol.12 (11), p.3297-3305

2006

Volltextzugriff (PDF)

Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies

Seminars in oncology, 2015-06, Vol.42 (3), p.448-458

2015

Volltextzugriff (PDF)

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours

Cardiovascular research, 2010-04, Vol.86 (1), p.12-19

2010

Volltextzugriff (PDF)

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Cancer Immunology, Immunotherapy, 2013-06, Vol.62 (6), p.1021-1028

2013

Volltextzugriff (PDF)

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Journal of translational medicine, 2004-06, Vol.2 (1), p.21-21, Article 21

2004

Volltextzugriff (PDF)

Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells

Cancer Immunology, Immunotherapy, 2002-03, Vol.51 (1), p.9-14

2002

Volltextzugriff (PDF)

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1393, p.133

2016

Volltextzugriff (PDF)

Thymosin alpha 1 in melanoma: from the clinical trial setting to the daily practice and beyond

Annals of the New York Academy of Sciences, 2012-10, Vol.1270 (1), p.8-12

2012

Volltextzugriff (PDF)

The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals

Reviews in health care, 2014-01, Vol.5 (1), p.3-6

2014

Volltextzugriff (PDF)

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

Journal of translational medicine, 2008-02, Vol.6 (1), p.8-8, Article 8

2008

Volltextzugriff (PDF)

Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome

Cancer immunology research, 2019-01, Vol.7 (1), p.12-28

2019

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(73)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(76)
Buchkapitel
(2)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

BRAF/NRAS Mutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer

Biology and Clinical Applications of CD40 in Cancer Treatment

Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness

Intratumor heterogeneity of cancer/testis antigens expression in human cutaneous melanoma is methylation-regulated and functionally reverted by 5-aza-2'-deoxycytidine

Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications

Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond

Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2′-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications

Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study

Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?

Endoglin Is a Suitable Target for Efficient Imaging of Solid Tumors: In Vivo Evidence in a Canine Mammary Carcinoma Model

The Coincidence of Chromosome 15 Aberrations and β2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma

Immunologic Correlates in the Course of Treatment With Immunomodulating Antibodies

Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours

Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme

Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?

Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells

ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies

Thymosin alpha 1 in melanoma: from the clinical trial setting to the daily practice and beyond

The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome

Suchergebnisse filtern